134 related articles for article (PubMed ID: 27166396)
1. Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or Frenemy?
Chua ML; Bristow RG
Clin Cancer Res; 2016 Jul; 22(13):3124-6. PubMed ID: 27166396
[TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.
Hedayati M; Haffner MC; Coulter JB; Raval RR; Zhang Y; Zhou H; Mian O; Knight EJ; Razavi N; Dalrymple S; Isaacs JT; Santos A; Hales R; Nelson WG; Yegnasubramanian S; DeWeese TL
Clin Cancer Res; 2016 Jul; 22(13):3310-3319. PubMed ID: 26831716
[TBL] [Abstract][Full Text] [Related]
3. Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer.
Zamagni A; Zanoni M; Cortesi M; Arienti C; Pignatta S; Naldini A; Sarnelli A; Romeo A; Tesei A
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182844
[TBL] [Abstract][Full Text] [Related]
4. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.
Denmeade SR; Isaacs JT
Prostate; 2010 Oct; 70(14):1600-7. PubMed ID: 20607766
[TBL] [Abstract][Full Text] [Related]
5. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
Rove KO; Crawford ED
Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
[TBL] [Abstract][Full Text] [Related]
6. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
7. Comparison of various hormonal therapies for prostatic carcinoma.
Geller J; Albert JD
Semin Oncol; 1983 Dec; 10(4 Suppl 4):34-41. PubMed ID: 6199846
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling.
Molina A; Belldegrun A
J Urol; 2011 Mar; 185(3):787-94. PubMed ID: 21239012
[TBL] [Abstract][Full Text] [Related]
9. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
10. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.
Griffiths K; Morton MS; Nicholson RI
Eur Urol; 1997; 32 Suppl 3():24-40. PubMed ID: 9267783
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
Blas L; Shiota M
Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
[No Abstract] [Full Text] [Related]
12. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
[TBL] [Abstract][Full Text] [Related]
13. The androgen receptor for the radiation oncologist.
Quero L; Rozet F; Beuzeboc P; Hennequin C
Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
[TBL] [Abstract][Full Text] [Related]
14. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
15. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
16. Role of radiation and androgen deprivation therapy for advanced prostate cancer.
Jani AB; Rossi PJ
Curr Probl Cancer; 2015; 39(1):41-7. PubMed ID: 25554467
[No Abstract] [Full Text] [Related]
17. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
18. Management of hormone-sensitive metastatic prostate cancer.
Agarwal N; Hussain M
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1221-41, viii. PubMed ID: 24188260
[TBL] [Abstract][Full Text] [Related]
19. Endocrine therapy for prostate cancer.
Labrie F
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):845-72. PubMed ID: 1778180
[TBL] [Abstract][Full Text] [Related]
20. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
